The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
And the hardest of all is the type 3 because you're having to find out...for example, some people have very high ERMI scores, that's EPA Relative Mold Index. If you've got mycootoxins being produced and you're living in them, you need to get out of there.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
So, although type 3, this toxin type represented only about 15% or 20% of all of the methapure [SP], over 50%, so typically in the 60% to 70% range had at least some suggestion of the type 3.